Human JAK1 Protein, His Tag
Human JAK1, His Tag (JA1-H5547) is expressed from Baculovirus-Insect cells. It contains AA Ala 561 - Asn 852 (Accession #
Predicted N-terminus: Met
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 35.7 kDa. The protein migrates as 30-33 kDa under reducing (R) condition (SDS-PAGE).
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Delivered as bulk protein in a 0.2 μm filtered solution of 50 mM Tris, 500 mM NaCl, 2 mM TCEP, pH8.0 with glycerol as protectant.
Contact us for customized product form or formulation.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt; -70 °C for 3 months under sterile conditions.
This product is supplied as sterile liquid solution and shipped frozen with dry ice, please inquire the shipping cost.
Human JAK1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. It interacts with the common gamma chain (γc) of type I cytokine receptors, to elicit signals from the IL-2 receptor family (e.g. IL-2R, IL-7R, IL-9R and IL-15R), the IL-4 receptor family (e.g. IL-4R and IL-13R), the gp130 receptor family (e.g. IL-6R, IL-11R, LIF-R, OSM-R, cardiotrophin-1 receptor (CT-1R), ciliary neurotrophic factor receptor (CNTF-R), neurotrophin-1 receptor (NNT-1R) and Leptin-R). Jak1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body
Clinical and Translational Updates
Promotion & Exhibitions
Accurately evaluate CAR expression level and CAR-T cell persistence in clinical trials
Request for Slides
bioSeedin webinar 17th——《GM-CSF Antibody for the Treatment of CRS in COVID-19》
Request for Slides
Drug Development Status
Number of Launched Drugs：5 Details
Number of Drugs in Clinical Trials：13 Details
Latest Research Phase：Approved
Datasheet & Documentation
+1 800-810-0816 (US)
+86 400-682-2521 (AP)
New Product Launch
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
SARS-CoV-2 Related Kits
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
Targets of CAR-T Cell Therapy
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full-length Transmembrane Proteins
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
Questions & Comments
This web search service is supported by Google Inc.